Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection Publicly, the company maintains confidence in its drug. It’s not clear why

https://www.statnews.com/2026/08/20/capricor-therapeutics-duchenne-treatment-fda/ By Adam FeuersteinAug. 20, 2026 Senior Writer, Biotech